中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
27期
4-5,6
,共3页
王宗站%周宓%田莹莹%邢晓波
王宗站%週宓%田瑩瑩%邢曉波
왕종참%주복%전형형%형효파
埃克替尼%脑转移%肺癌
埃剋替尼%腦轉移%肺癌
애극체니%뇌전이%폐암
Icotinib%Brain metastases%Lung cancer
目的：分析埃克替尼联合全脑放疗治疗老年肺腺癌脑转移的疗效及不良反应。方法57例肺腺癌脑转移患者,均为不能耐受化疗或不愿接受化疗的老年患者,根据治疗方法的不同分为靶向联合放疗组(27例)及单纯放疗组(30例)。观察并比较两组治疗有效率、中位生存时间、不良反应。结果靶向联合放疗组与单纯放疗组患者有效率(81.5%VS 40.0%)及疾病控制率(96.3%VS 73.3%)比较,差异均有统计学意义(P<0.05)；靶向联合放疗组中位生存时间11个月,1年生存率51.9%；单纯放疗组中位生存时间7个月,1年生存率23.3%。两组1年生存率比较,差异有统计学意义(P=0.02<0.05)。靶向联合放疗组主要不良反应为皮疹,皮疹发生率为63.0%,有2例患者皮疹达4级,经对症处理,能耐受继续口服靶向药物。结论埃克替尼联合放疗治疗老年肺腺癌脑转移疗效好,不良反应少,值得临床推广应用。
目的：分析埃剋替尼聯閤全腦放療治療老年肺腺癌腦轉移的療效及不良反應。方法57例肺腺癌腦轉移患者,均為不能耐受化療或不願接受化療的老年患者,根據治療方法的不同分為靶嚮聯閤放療組(27例)及單純放療組(30例)。觀察併比較兩組治療有效率、中位生存時間、不良反應。結果靶嚮聯閤放療組與單純放療組患者有效率(81.5%VS 40.0%)及疾病控製率(96.3%VS 73.3%)比較,差異均有統計學意義(P<0.05)；靶嚮聯閤放療組中位生存時間11箇月,1年生存率51.9%；單純放療組中位生存時間7箇月,1年生存率23.3%。兩組1年生存率比較,差異有統計學意義(P=0.02<0.05)。靶嚮聯閤放療組主要不良反應為皮疹,皮疹髮生率為63.0%,有2例患者皮疹達4級,經對癥處理,能耐受繼續口服靶嚮藥物。結論埃剋替尼聯閤放療治療老年肺腺癌腦轉移療效好,不良反應少,值得臨床推廣應用。
목적：분석애극체니연합전뇌방료치료노년폐선암뇌전이적료효급불량반응。방법57례폐선암뇌전이환자,균위불능내수화료혹불원접수화료적노년환자,근거치료방법적불동분위파향연합방료조(27례)급단순방료조(30례)。관찰병비교량조치료유효솔、중위생존시간、불량반응。결과파향연합방료조여단순방료조환자유효솔(81.5%VS 40.0%)급질병공제솔(96.3%VS 73.3%)비교,차이균유통계학의의(P<0.05)；파향연합방료조중위생존시간11개월,1년생존솔51.9%；단순방료조중위생존시간7개월,1년생존솔23.3%。량조1년생존솔비교,차이유통계학의의(P=0.02<0.05)。파향연합방료조주요불량반응위피진,피진발생솔위63.0%,유2례환자피진체4급,경대증처리,능내수계속구복파향약물。결론애극체니연합방료치료노년폐선암뇌전이료효호,불량반응소,치득림상추엄응용。
Objective To analyze curative effect and adverse reactions of icotinib combined with whole brain radiotherapy in the treatment of senile lung adenocarcinoma with brain metastases patients. Methods A total of 57 senile lung adenocarcinoma with brain metastases patients, without receiving chemotherapy, were divided by different treatment methods into targeted combined radiotherapy group (27 cases) and single radiotherapy group (30 cases). Effective rate, median survival time, survivorship curve, and adverse reactions of the two groups were observed and compared. Results There were statistically significant differences of effective rate (81.5%VS 40.0%) and disease control rate (96.3%VS 73.3%) between the targeted combined radiotherapy group and the single radiotherapy group (P<0.05). The targeted combined radiotherapy group had median survival time as 11 months and 1 year survival rate as 51.9%, and those in the single radiotherapy group were 7 months and 23.3%. The difference of 1 year survival rate between the two groups had statistical significance (P=0.02<0.05). Main adverse reactions in the targeted combined radiotherapy group was rash, with the occurrence rate as 63.0%. There were 2 cases with grade 4 rash, and they received continuous targeted drug by oral administration after symptomatic treatment. Conclusion Implement of icotinib combined with radiotherapy provides good curative effect and few adverse reactions in treating senile lung adenocarcinoma with brain metastases patients. It is worth clinical promotion and application.
